Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EO2318
- Development stage
- Unknown
- Lead developer
- Enterome
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
EO2318 is an innovative OncoMimic peptide-based immunotherapy developed by Enterome, specifically targeting mismatch repair proficient (pMMR) and microsatellite stable (MSS) colorectal adenocarcinoma. The drug is based on Enterome's proprietary Mimicry platform, which identifies bacterial peptides from the human gut microbiome that share high structural similarity with tumor-associated antigens (TAAs). By administering these synthetic bacterial mimics, EO2318 aims to activate and expand pre-existing memory T cells that were originally primed by the microbiome, redirecting them to recognize and eliminate cancer cells. This approach is designed to overcome the low immunogenicity typically associated with MSS CRC, which often fails to respond to standard checkpoint inhibitors. EO2318 is currently being evaluated in clinical trials in combination with immune checkpoint inhibitors and standard-of-care chemotherapy to enhance anti-tumor immune responses.
02
Targets
Tumor-associated antigens mimicked by EO2318-derived peptidesγδ TCR (T-cell receptor)
Beyond the preview
Go deeper on EO2318.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EO2318.